UGT1A9 and colorectal cancer: Studies have also indicated that the UGT1A7 and/or UGT1A9 genotypes may be predictors of response and toxicity in colorectal cancer (CRC) patients treated with capecitabine and irinotecan (Carlini et al., 2005).